Articles tagged with Vascular Endothelial Growth Factor
A new study found that vascular endothelial growth factor (VEGF) plays a key role in the onset of sepsis, a leading cause of organ failure and ICU hospitalizations. The study's findings suggest that VEGF could be a novel therapeutic agent for managing this deadly disease.
Researchers found that placental growth factor levels are higher in heart attack patients and correlate with cardiac function improvement. The study suggests PlGF promotes tissue repair after a heart attack by mobilizing stem cells.
A new mouse model reveals that moderate alcohol consumption fuels blood vessel growth and encourages cancer tumors, increasing the risk of cancer. The study suggests that blocking VEGF over-production could reduce cancer incidence and provides a potential tool for cancer education and prevention.
Researchers found that GM-CSF treatment increased circulating endothelial progenitor cells, improving walking ability without pain. The therapy also showed promise for reducing vascular function risk and atherosclerosis.
A Joslin Diabetes Center study reveals insulin's critical role in blood vessel formation, which may lead to new treatments for heart attacks in diabetes patients. The researchers found that insulin activates a pathway producing VEGF, essential for new blood vessel growth.
A UK researcher found that VEGF promotes angiogenesis in macular degeneration, but also has an anti-angiogenic effect via SPARC. Controlling SPARC levels may be key to controlling angiogenesis in diseases like cancer. This discovery opens new avenues for treating diseases related to angiogenesis.
Researchers found that early detection and treatment of age-related macular degeneration with pegaptanib sodium can help patients maintain and, in some cases, regain vision. Patients treated with pegaptanib had a significantly better prognosis than those receiving usual care.
Researchers at Yale University have identified a potential new target for treating vascular disease by inhibiting the protein kinase Akt1. The study found that Akt1 plays a crucial role in the formation of new blood vessels, which is essential for improving blood flow to muscles during exercise.
Researchers at Medical College of Georgia have developed a new approach to inhibit blood vessel growth by targeting VEGF production within cells. The technique, which uses a gene that binds to and sequesters VEGF, has shown promising results in reducing destructive blood vessel proliferation by up to two-thirds.
Researchers at NYU School of Medicine discovered that glycyrrhizic acid can kill cells infected with Kaposi sarcoma-associated herpesvirus, triggering apoptosis in transformed B lymphocytes. This finding suggests a potential new treatment approach for latent viral infections.
Researchers found BDNF is as effective as VEGF in inducing growth of tiny blood vessels in organs with TrkB-expressing cells. It recruits blood stem cells that contribute to neo-angiogenesis, providing a novel therapeutic protein for organ-specific angiogenesis.
A study published in the Journal of the American Medical Association finds that women with low levels of placental growth factor (PlGF) in their urine are highly likely to develop preeclampsia. Researchers plan to refine this finding into a clinical test to screen for high-risk pregnancies.
The study demonstrates a statistically significant and clinically meaningful benefit of pegaptanib in treating wet AMD. Treatment with pegaptanib reduces the risk of visual-acuity loss, promotes stability of vision, and may lead to more visual improvement in some patients.
Scientists have discovered a way to manage angiogenesis by stimulating monocytes with GM-CSF, which produces soluble receptors that inhibit the formation of new blood vessels. The approach could provide a new therapeutic strategy for cancer treatment.
A recent study found that ethanol exposure increases tumor size, blood vessel density, and VEGF levels in chick embryos, supporting the hypothesis that ethanol-induced angiogenesis contributes to cancer progression. The study provides new insights into the mechanisms underlying alcohol's association with various types of cancer.
Researchers found that green tea polyphenols reduce levels of insulin-like growth factor-1 (IGF-1) in prostate tumor cells, leading to decreased cell survival and tumor growth. The study also showed that GTP inhibited the expression of proteins associated with metastasis and reduced vascular endothelial growth factor (VEGF) levels.
ALS researchers found that continuous administration of VEGF protein into the cerebrospinal fluid increases life expectancy in ALS rats. The treatment has shown promising results with a patient-oriented approach, allowing controlled doses to be easily administered.
Researchers found that exercise increases VEGF production, which leads to an increase in capillaries within specific muscle fiber types. This change ultimately results in an anaerobic to aerobic shift in the affected muscle fibers.
A team of researchers has discovered a new form of vascular endothelial growth factor (VEGF) called VEGF165b, which inhibits the growth of new blood vessels required for tumours to grow above one millimetre. This protein is found in normal tissues and can prevent cancer growth by starving tumours of nutrients.
Researchers at Scripps Research Institute use a class of compounds known as Src kinase inhibitors to stabilize blood vessels and block tumor cell metastasis. By increasing the protective barrier strength of host blood vessels, the approach prevents cancer cells from exiting the bloodstream, making them vulnerable to immune system attack.
Researchers have discovered new approaches to treating ALS using genetic techniques and growth factors. A study found that implanting cells to support motor neurons can help stave off the disease, while another team used RNA interference to silence a toxic mutant gene. VEGF was also shown to rescue motor neurons attacked by ALS.
Researchers have successfully developed a gene therapy approach to treat peripheral arterial disease, stimulating blood vessel growth and improving perfusion in damaged leg tissue. The treatment also appeared to prevent programmed cell death, as the researchers reported.
A study published in Nature Medicine found that the VEGF molecule plays a significant role in the development of asthma by inducing asthma-like abnormalities in genetically engineered mice. The researchers also discovered that blocking VEGF can prevent these manifestations, suggesting new potential targets for treatment.
A study found that cannabinoids significantly lowered VEGF activity in laboratory mice and patients with late-stage glioblastoma, providing a potential new approach to treating this aggressive form of cancer. The research suggests that cannabinoid-based therapies may target the VEGF pathway, offering a novel pharmacological target.
A new study by the Schepens Eye Research Institute reveals a previously unknown connection that stimulates immune response in the eye and other parts of the body. By blocking VEGFR-3 growth factor, researchers can arrest the rejection process, leading to improved survival rates for corneal transplant patients.
Researchers found Veglin to be safe and effective in lowering blood levels of key enzymes, showing promise in blocking tumor growth and metastasis. The phase I trial has shown encouraging results in patients with diverse disease types, paving the way for future phase II clinical trials.
Researchers have discovered that a gene therapy using growth factor VEGF can slow down the onset and progression of ALS in mice, increasing life expectancy by 30%. This treatment has shown promising results without toxic side effects, offering new hope for patients with this incurable disease.
A study published in Investigative Ophthalmology & Visual Science found that breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula, and improved visual acuity in some cases. The therapy was found to reduce excess thickness of the macula by an average of 43 percent.
Researchers found an inverse correlation between Rb2 expression and VEGF in liver tumors. The study suggests that lower Rb2 expression and higher VEGF levels can predict the aggressiveness of liver cancer, regardless of tumor stage.
A new mouse model of SBMA has been created, showing that the abnormal androgen receptor interferes with vascular endothelial growth factor (VEGF) production, leading to motor neuron degeneration. The study suggests VEGF may play a pivotal role in protecting motor neurons from damage.
Researchers at Stanford University found that microenvironmental VEGF concentration determines the threshold between normal and aberrant blood vessel growth. Long-term continuous delivery of VEGF maintains below this threshold promotes normal angiogenesis, guiding therapeutic strategies.
The calcium-sensing receptor plays a crucial role in regulating mammary gland function, influencing milk production and composition. This study demonstrates that the receptor helps match milk production with available calcium levels in the mother's body.
Researchers have identified elevated levels of soluble fms-like tyrosine kinase 1 (sFlt1) in pregnant women at risk of developing preeclampsia. This finding suggests that sFlt1 may serve as a biomarker for early detection and potentially inform treatment strategies through the administration of drug therapies that neutralize its effects.
Researchers found that elevated sFlt-1 levels and low PlGF levels can predict the development of preeclampsia. Women with preeclampsia also have lower VEGF levels, which may contribute to the condition's health problems.
Researchers found a correlation between genetic variations in the VEGF gene and psoriasis susceptibility. This discovery may lead to targeted therapies blocking the activity of VEGF, which could provide relief for patients.
Researchers have identified c-myc as a key regulator of hormone-dependent prostate cancer cell growth, potentially leading to new treatment targets. Meanwhile, a novel approach using regulatory T cells has shown promise in controlling graft-versus-host disease, while a study on mast cells reveals their role in allergic diarrhea and pot...
Scientists have developed new therapies targeting survivin and VEGF to induce cancer cell death. LY2181308 inhibits survivin expression, while a novel VEGF receptor, R2Fas, triggers apoptosis in blood vessels and cancer cells. These approaches show promise for treating various types of cancers.
Researchers at Thomas Jefferson University have found that combining radiation with VEGF Trap, a protein engineered to block angiogenesis activity, can delay tumor growth by up to 40 days. The study suggests that radiation may enhance the effectiveness of VEGF Trap in treating glioblastoma, a common and aggressive brain tumor.
Researchers discover PlGF-1 stabilizes vessel growth in premature infants, preventing retinal detachment and blindness. The study suggests a promising therapeutic agent to prevent oxygen-induced vascular degeneration in ROP.
Researchers developed VEGF-TRAP, an injection that prevents new blood vessel growth in the eyes of mice. The treatment halted existing vessel leakage and showed long-lasting effects without complications. It may offer a potential treatment for diabetic retinopathy and macular degeneration.
Schepens Eye Research Institute scientists have discovered a new drug that can trap abnormal growth factors in the cornea, potentially improving corneal transplants. Additionally, a gene therapy approach has shown promise in preventing and treating autoimmune diseases like uveitis by inducing a protein called a-MSH.
Researchers found that celecoxib capsules stop the Sp1 transcription factor from activating genes associated with cancer growth. This led to reduced production of VEGF, a key angiogenic factor that feeds tumors. The study provides a novel molecular mechanism for celecoxib's antitumor activity and may lead to tailored treatment options.
A clinical trial using VEGF gene transfer found no significant improvement in walking ability for patients with peripheral arterial disease (PAD). Researchers are exploring alternative approaches, including transcription factor-based therapies and cell therapy, to address the condition.
Research on STI571 and paclitaxel shows potential in controlling prostate cancer metastasis to bone. Lung cancer risk varies widely among smokers, with accurate prediction models helping individuals decide on screening. Non-BRCA mutations may be linked to high breast cancer risk in younger women.
Researchers identified sFlt1 as the root cause of preeclampsia, a condition characterized by high blood pressure and organ damage. The study's findings hold promise for developing diagnostic tools and therapies for this deadly condition.
Scientists found that elevated levels of sFlt1 protein mediate the progression to preeclampsia by reducing angiogenic factors. Reducing VEGF-A in kidney cells also caused similar kidney disease, suggesting a plausible scenario for preeclampsia
A researcher is studying how tumors pirate angiogenesis, the formation of new blood vessels, to survive. Dr. Motamed focuses on protein SPARC, which regulates growth factors and has multiple roles in cancer and new blood vessel formation.
A gene involved in forming blood vessels has been identified as a key player in DiGeorge syndrome, a chromosomal abnormality causing devastating birth defects. The study found that abnormalities in VEGF lead to the syndrome, which affects the heart, thymus, parathyroid gland, and mental retardation.
Researchers found that bone marrow cell transplantation significantly increased new capillary formation and improved blood flow in patients with PAD. The study's findings suggest that this therapy may help alleviate symptoms of PAD, including pain, fatigue, and ischemic ulcers, by promoting angiogenesis.
Researchers investigated the physiological roles of VEGF isoforms in embryonic vascular development, finding that different isoforms have distinct functions and are necessary for normal vessel branching frequency and width. The study uses transgenic mice to explore the role of soluble and heparin-binding VEGF isoforms in vessel growth.
Researchers discovered that bone marrow cells can form new blood vessels in newborns, contrary to previous belief that this process only occurs before birth. The study also found that VEGF accelerates the formation of new blood vessels, with implications for tumor biology and congenital disorders.
Researchers found that inhaled corticosteroids significantly improved disease symptoms and reduced patient exacerbations in a double-blind study of COPD patients. However, ICS treatment had no effect on major inflammatory cell types or lung function in this advanced COPD population.
Researchers have developed a new technique using the vascular endothelial growth factor (VEGF) as a carrier to deliver a toxic agent selectively to tumor blood vessels. This approach has shown impressive anti-tumor effects in mice with human melanoma and prostate cancer, reducing tumor growth by up to 16 percent.
Researchers discovered the ancestral role of VEGF protein guiding developing blood cells to their destinations. The findings suggest that blood vessels may have evolved from blood cells, a theory supported by studies on fruit fly embryos.
Glioma cells induce angiogenesis by interacting with host vasculature and sprouting new vessels, defying the cooptation model. Vascular outgrowth occurs as a continuous process of growth and remodeling, starting early in tumor progression.
Researchers genetically engineered mice to overexpress the HIF-1α gene in skin cells, resulting in a 70% increase in capillaries and normal-like blood vessels. The study suggests that HIF-1α harnesses VEGF expression in a way that could be beneficial therapeutically for conditions like ischemic tissue and recalcitrant wounds.
Researchers at the University of Michigan successfully grew new, mature blood vessels in live animals by implanting scaffolds that delivered critical growth factors. The innovative approach, reported in Nature Biotechnology, has potential medical applications for alternatives to heart bypass surgery and treatments for vascular disease.
Researchers at the University of Michigan have developed a new tissue engineering method that uses a polymer to encourage the formation of healthy blood vessels in living rats. The approach, which combines VEGF and PDGF growth factors, shows promise for treating coronary artery disease and speeding up wound healing.
In two studies, VEGF gene therapy significantly reduced angina episodes and improved exercise tolerance in patients with end-stage coronary heart disease. The treatment has shown impressive clinical results, with most patients experiencing continued improvement in daily life after treatment.
Researchers at UCSF have discovered that continuous expression of the HIF-1a gene can induce formation of new blood vessels in mice. This breakthrough has significant therapeutic potential for treating diseases such as diabetes and recalcitrant wounds.